Eventide Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-359,000
| Closed | -$16.8M | – | 167 |
|
|
2024
Q1 | $16.8M | Hold |
359,000
| – | – | 0.26% | 103 |
|
|
2023
Q4 | $17.2M | Hold |
359,000
| – | – | 0.28% | 92 |
|
|
2023
Q3 | $12.8M | Hold |
359,000
| – | – | 0.23% | 113 |
|
|
2023
Q2 | $16.6M | Hold |
359,000
| – | – | 0.28% | 95 |
|
|
2023
Q1 | $14.4M | Hold |
359,000
| – | – | 0.26% | 103 |
|
|
2022
Q4 | $16.6M | Buy |
359,000
+53,200
| +17% | +$2.46M | 0.33% | 89 |
|
|
2022
Q3 | $12.7M | Buy |
+305,800
| New | +$12.7M | 0.25% | 97 |
|
|
2018
Q4 | – | Sell |
-87,400
| Closed | -$6.67M | – | 146 |
|
|
2018
Q3 | $6.67M | Hold |
87,400
| – | – | 0.25% | 94 |
|
|
2018
Q2 | $6.72M | Hold |
87,400
| – | – | 0.28% | 87 |
|
|
2018
Q1 | $4.46M | Hold |
87,400
| – | – | 0.21% | 91 |
|
|
2017
Q4 | $4.05M | Hold |
87,400
| – | – | 0.21% | 88 |
|
|
2017
Q3 | $4.66M | Hold |
87,400
| – | – | 0.26% | 79 |
|
|
2017
Q2 | $5.43M | Hold |
87,400
| – | – | 0.34% | 68 |
|
|
2017
Q1 | $5.92M | Hold |
87,400
| – | – | 0.39% | 67 |
|
|
2016
Q4 | $6.15M | Hold |
87,400
| – | – | 0.4% | 64 |
|
|
2016
Q3 | $6.2M | Hold |
87,400
| – | – | 0.38% | 69 |
|
|
2016
Q2 | $4.28M | Hold |
87,400
| – | – | 0.26% | 75 |
|
|
2016
Q1 | $5.53M | Hold |
87,400
| – | – | 0.31% | 71 |
|
|
2015
Q4 | $9.81M | Sell |
87,400
-18,100
| -17% | -$2.03M | 0.49% | 57 |
|
|
2015
Q3 | $10.2M | Buy |
105,500
+21,400
| +25% | +$2.06M | 0.59% | 52 |
|
|
2015
Q2 | $8.61M | Buy |
84,100
+15,100
| +22% | +$1.55M | 0.47% | 59 |
|
|
2015
Q1 | $4.28M | Buy |
69,000
+16,400
| +31% | +$1.02M | 0.32% | 73 |
|
|
2014
Q4 | $2.31M | Hold |
52,600
| – | – | 0.25% | 76 |
|
|
2014
Q3 | $2.98M | Hold |
52,600
| – | – | 0.42% | 64 |
|
|
2014
Q2 | $2.36M | Buy |
+52,600
| New | +$2.36M | 0.32% | 71 |
|